The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
November 11, 2024
View Complete Issue         Table of Contents 2019 
Vorasidenib (Voranigo) for Low-Grade Glioma (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Vorasidenib (Voranigo) for Low-Grade Glioma (online only)
November 11, 2024 (Issue: 1715)
The FDA has approved vorasidenib (Voranigo – Servier), an oral isocitrate dehydrogenase (IDH) inhibitor, for treatment of grade 2 astrocytoma or oligodendroglioma in patients ≥12 years old with an IDH1 or IDH2 mutation. It is the first...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Vorasidenib (Voranigo) for Low-Grade Glioma (online only)
Article code: 1715g
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.